The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Urothelium

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Urothelium

 

High impact information on Urothelium

  • RESULTS: Sodium saccharin treatment had no effect on the urine or urothelium in any of these monkeys [6].
  • Because proHB-EGF is known to be the high affinity diphtheria toxin (DT) receptor in human cells, synthesis of the HB-EGF precursor by human urothelium also suggests the possibility of using the DT-binding sites of proHB-EGF as an in vivo target for the intraluminal treatment of urothelial diseases [7].
  • Studies on sections representing different stages of neoplastic progression showed disruption in the antibody-staining pattern in urothelium and, in all cases, a strong distinct staining of invasive tumor areas and metastatic secondary tumors [8].
  • An antigen, termed "urothelium membrane antigen" (UMA), confined to urothelium and most abundantly associated with the asymmetric unit membrane of the terminally differentiated luminal cells was identified with a monospecific (absorbed or affinity purified) rabbit antiserum obtained by immunization with membranes from normal bovine urothelium [9].
  • At 0.5% saccharin, urothelium on explant surfaces resembled that of controls, except in one instance in which mild focal hyperplasia persisted [10].
 

Chemical compound and disease context of Urothelium

 

Biological context of Urothelium

 

Anatomical context of Urothelium

 

Associations of Urothelium with chemical compounds

  • Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study [24].
  • PURPOSE: Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium [25].
  • CONCLUSION: This combination of paclitaxel, cisplatin, and gemcitabine is feasible and highly active in patients with advanced TCC of the urothelium [11].
  • At 8, 14, and 20 weeks after the last MNU administration, urothelial polyamine levels and [3H] thymidine incorporation by the urothelium of HTBs were determined in nine rats of Groups 1 and 2 [26].
  • Aberrant cyclic adenosine 3':5'-monophosphate metabolism in cultures of tumorigenic rat urothelium [27].
 

Gene context of Urothelium

 

Analytical, diagnostic and therapeutic context of Urothelium

References

  1. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. Gabrilove, J.L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M.A., Clarkson, B. N. Engl. J. Med. (1988) [Pubmed]
  2. ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. Viola, M.V., Fromowitz, F., Oravez, S., Deb, S., Schlom, J. J. Exp. Med. (1985) [Pubmed]
  3. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Neal, D.E., Marsh, C., Bennett, M.K., Abel, P.D., Hall, R.R., Sainsbury, J.R., Harris, A.L. Lancet (1985) [Pubmed]
  4. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. Hu, P., Deng, F.M., Liang, F.X., Hu, C.M., Auerbach, A.B., Shapiro, E., Wu, X.R., Kachar, B., Sun, T.T. J. Cell Biol. (2000) [Pubmed]
  5. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cheng, J., Huang, H., Zhang, Z.T., Shapiro, E., Pellicer, A., Sun, T.T., Wu, X.R. Cancer Res. (2002) [Pubmed]
  6. Long-term feeding of sodium saccharin to nonhuman primates: implications for urinary tract cancer. Takayama, S., Sieber, S.M., Adamson, R.H., Thorgeirsson, U.P., Dalgard, D.W., Arnold, L.L., Cano, M., Eklund, S., Cohen, S.M. J. Natl. Cancer Inst. (1998) [Pubmed]
  7. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. Freeman, M.R., Yoo, J.J., Raab, G., Soker, S., Adam, R.M., Schneck, F.X., Renshaw, A.A., Klagsbrun, M., Atala, A. J. Clin. Invest. (1997) [Pubmed]
  8. Monoclonal antibodies raised against cell membrane components of human bladder tumor tissue recognizing subpopulations in normal urothelium. Summerhayes, I.C., McIlhinney, R.A., Ponder, B.A., Shearer, R.J., Pocock, R.D. J. Natl. Cancer Inst. (1985) [Pubmed]
  9. Species cross-reactive membrane-associated urothelial differentiation antigen. Trejdosiewicz, L.K., Wilson, P.D., Hodges, G.M. J. Natl. Cancer Inst. (1984) [Pubmed]
  10. N-Methyl-N-nitrosourea and saccharin: effects on epithelium of normal human urinary bladder in vitro. El-Gerzawi, S., Heatfield, B.M., Trump, B.F. J. Natl. Cancer Inst. (1982) [Pubmed]
  11. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. Bellmunt, J., Guillem, V., Paz-Ares, L., González-Larriba, J.L., Carles, J., Batiste-Alentorn, E., Sáenz, A., López-Brea, M., Font, A., Nogué, M., Bastús, R., Climent, M.A., de la Cruz, J.J., Albanell, J., Banús, J.M., Gallardo, E., Diaz-Rubio, E., Cortés-Funes, H., Baselga, J. J. Clin. Oncol. (2000) [Pubmed]
  12. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. Small, E.J., Lew, D., Redman, B.G., Petrylak, D.P., Hammond, N., Gross, H.M., Eastham, J.A., Crawford, E.D. J. Clin. Oncol. (2000) [Pubmed]
  13. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Simeonova, P.P., Wang, S., Toriuma, W., Kommineni, V., Matheson, J., Unimye, N., Kayama, F., Harki, D., Ding, M., Vallyathan, V., Luster, M.I. Cancer Res. (2000) [Pubmed]
  14. Mitogenic effects of propoxur on male rat bladder urothelium. Cohen, S.M., Cano, M., Johnson, L.S., StJohn, M.K., Asamoto, M., Garland, E.M., Thyssen, J.H., Sangha, G.K., van Goethem, D.L. Carcinogenesis (1994) [Pubmed]
  15. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Lin, J.H., Zhao, H., Sun, T.T. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  16. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma. Retz, M., Lehmann, J., Röder, C., Plötz, B., Harder, J., Eggers, J., Pauluschke, J., Kalthoff, H., Stöckle, M. Cancer Res. (1998) [Pubmed]
  17. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Garcia-España, A., Salazar, E., Sun, T.T., Wu, X.R., Pellicer, A. Cancer Res. (2005) [Pubmed]
  18. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ. Bindels, E.M., Vermey, M., van den Beemd, R., Dinjens, W.N., Van Der Kwast, T.H. Cancer Res. (2000) [Pubmed]
  19. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. Bader, B.L., Magin, T.M., Hatzfeld, M., Franke, W.W. EMBO J. (1986) [Pubmed]
  20. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Piazza, G.A., Thompson, W.J., Pamukcu, R., Alila, H.W., Whitehead, C.M., Liu, L., Fetter, J.R., Gresh, W.E., Klein-Szanto, A.J., Farnell, D.R., Eto, I., Grubbs, C.J. Cancer Res. (2001) [Pubmed]
  21. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Reubi, J.C., Läderach, U., Waser, B., Gebbers, J.O., Robberecht, P., Laissue, J.A. Cancer Res. (2000) [Pubmed]
  22. Activity of the human blood group ABO, Se, H, Le, and X gene-encoded glycosyltransferases in normal and malignant bladder urothelium. Orntoft, T.F., Wolf, H., Watkins, W.M. Cancer Res. (1988) [Pubmed]
  23. Induction of prostatic morphology and secretion in urothelium by seminal vesicle mesenchyme. Donjacour, A.A., Cunha, G.R. Development (1995) [Pubmed]
  24. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. Dreicer, R., Manola, J., Roth, B.J., Cohen, M.B., Hatfield, A.K., Wilding, G. J. Clin. Oncol. (2000) [Pubmed]
  25. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. Redman, B.G., Smith, D.C., Flaherty, L., Du, W., Hussain, M. J. Clin. Oncol. (1998) [Pubmed]
  26. Inhibition of carcinogenesis by alpha-difluoromethylornithine in heterotopically transplanted rat urinary bladders. Homma, Y., Ozono, S., Numata, I., Seidenfeld, J., Oyasu, R. Cancer Res. (1985) [Pubmed]
  27. Aberrant cyclic adenosine 3':5'-monophosphate metabolism in cultures of tumorigenic rat urothelium. Chlapowski, F.J., Nemecek, G.M. Cancer Res. (1985) [Pubmed]
  28. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cascorbi, I., Roots, I., Brockmöller, J. Cancer Res. (2001) [Pubmed]
  29. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Tomlinson, D.C., L'Hôte, C.G., Kennedy, W., Pitt, E., Knowles, M.A. Cancer Res. (2005) [Pubmed]
  30. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Oliveira-Ferrer, L., Tilki, D., Ziegeler, G., Hauschild, J., Loges, S., Irmak, S., Kilic, E., Huland, H., Friedrich, M., Ergün, S. Cancer Res. (2004) [Pubmed]
  31. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Ross, S., Spencer, S.D., Holcomb, I., Tan, C., Hongo, J., Devaux, B., Rangell, L., Keller, G.A., Schow, P., Steeves, R.M., Lutz, R.J., Frantz, G., Hillan, K., Peale, F., Tobin, P., Eberhard, D., Rubin, M.A., Lasky, L.A., Koeppen, H. Cancer Res. (2002) [Pubmed]
  32. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. Kuball, J., Wen, S.F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D.C., Grace, M.J., Fritz, M.A., Störkel, S., Thüroff, J.W., Huber, C., Schuler, M. J. Clin. Oncol. (2002) [Pubmed]
  33. Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Ulich, T.R., Whitcomb, L., Tang, W., O'Conner Tressel, P., Tarpley, J., Yi, E.S., Lacey, D. Cancer Res. (1997) [Pubmed]
  34. Alteration of the PATCHED locus in superficial bladder cancer. Aboulkassim, T.O., LaRue, H., Lemieux, P., Rousseau, F., Fradet, Y. Oncogene (2003) [Pubmed]
  35. ATP is released from guinea pig ureter epithelium on distension. Knight, G.E., Bodin, P., De Groat, W.C., Burnstock, G. Am. J. Physiol. Renal Physiol. (2002) [Pubmed]
 
WikiGenes - Universities